我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

冠心病急性心肌梗死并发糖尿病患者血清PPARγ的变化

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2009年第6期
页码:
848-850
栏目:
临床研究
出版日期:
2009-11-05

文章信息/Info

Title:
Relationship between PPARγ and coronary heart disease and acute myocardial infarction in diabetes
作者:
张瑞英; 莫成利; 富路; 康晓宁
哈尔滨医科大学附属一院心内科，黑龙江 哈尔滨 150001
Author(s):
ZHANG Rui-ying;  MO Cheng-li;  Fu Lu;  Kang Xiao-ning
Department of Cardiology, First Affiliated Hospital, Harbin Medical University, Harbin 150001, Heilongjiang, China
关键词:
过氧化物酶体增殖物激活受体γ; 冠状动脉疾病; 糖尿病; Ⅱ型
Keywords:
PPARγ;  coronary disease;  type II diabetes mellitus
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的: 探讨血清过氧化物酶体增殖物激活受体γ（PPARγ）与冠心病、Ⅱ型糖尿病并发急性心肌梗死(AMI)的关系。方法: 经冠脉造影证实的冠心病患者，分为稳定型心绞痛 (SAP)组、不稳定型心绞痛(UAP)组、AMI组、Ⅱ型糖尿病并发AMI（AD）组，经冠脉造影证实冠脉正常者为对照组。入院后抽取静脉血,测定PPARγ、血脂、空腹血糖（FPG）等。结果: 各组间比较PPARγ水平，SAP组与对照组无显著差异，UAP组、AMI组、DA组与对照组比较，PPARγ水平显著下降(P<0.01)。结论: 与单纯AMI组相比，AD组PPARγ降低更加显著。
Abstract:
AIM: To study the relationship between serum PPARγ level and coronary heart disease (CHD) and acute myocardial infarction (AMI) in type II diabetes mellitus (T2DM). METHODS: Patients diagnosed as having CHD by coronary artery opacification were divided into four groups: stable angina pectoris group (SAP), unstable angina pectoris group (UAP), AMI group, and AMI/T2DM group (AD). Subjects relieved from CHD by coronary artery opacification were selected as control group. Venous blood of all study subjects was taken to determine PPARγ, blood lipids and fasting blood glucose. RESULTS: No significant difference was found in PPARγ level between SAP group and control group. PPARγ levels in SAP group, UA group, AMI group and AD group were significantly lower than in control group (P<0.01). CONCLUSION: PPARγ level in patients with AMI complicated by T2DM is obviously lower than in patients with AMI.

参考文献/References

［1］ Harrington WW, S Britt C, G Wilson J, et al. The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-InducedObese AKR/J Mice［J］. PPAR Res, 2007, 2007:97125.

［2］ 杨丽霞，杨玉霞，齐峰，等. 可溶性-CD40配体和核转录因子PPARγ与冠状动脉病变的相关性研究［J］. 中国现代医学杂志，2006, 16(18):2792-2803.

［3］ Ghoussaini M, Meyre D, Lobbens S, et al. Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population［J］. BMC Med Genet, 2005, 6:11.

［4］ Yaffe K, Kanaya AM, Lindquist K, et al. PPARγ pro12Ala genotype and risk of cognitive decline in elders［J］. Neurobiol Aging, 2008, 29(1):78-83.

［5］ Gallicchio L, Kalesan B, Huang HY, et al. Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, maryland［J］. PPAR Res, 2008, 2008:276581.

［6］ Cohen RN. Nuclear receptor corepressors and PPARγ［J］. Nucl Recept Signal, 2006, 4:e003.

［7］ Yang B, Brown KK, Chen L, et al. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats［J］. BMC Pharmacol, 2004, 4:23.

［8］ Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome［J］. J Clin Invest, 2006, 116(7):1784-1792.

［9］ Ding G, Qin Q, He N, et al. Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator -activated receptor γ［J］. J Mol Cell Cardiol, 2007, 43(1):73-84.

［10］Stienstra R, Duval C, Müller M, et al. PPARs, Obesity, and Inflammation［J］. PPAR Res, 2007, 2007:95974.

［11］Glass CK. Going nuclear in metabolic and cardiovascular disease［J］. J Clin Invest, 2006, 116(3):556-560.

［12］Calkin AC, Thomas MC. PPAR Agonists and Cardiovascular Disease in Diabetes［J］. PPAR Res, 2008, 2008:245410.

备注/Memo

备注/Memo:
收稿日期：2008-8-26.基金项目：哈尔滨市学科后备带头人基金资助(2005AFXXJ047);省攻关课题项目资助（GC05C40304） 作者简介：张瑞英，主任医师Email:zhangruiyingha@126.com
更新日期/Last Update: 2009-09-30